Orphan Drug Designation Expanded for Mobius Therapeutics’ Mitosol

November 3, 2017: By Jon Swedien

download (1)

Mobius Therapeutics announced Oct. 31 that the orphan drug designation for Mitosol has been changed to read: “treatment of refractory glaucoma as an adjunct to surgery.”

Mitosol is an ophthalmic reformulation of mitomycin C for use in glaucoma surgery. The new designation lays the groundwork for Mobius to pursue an expanded indication for Mitosol that would include refractory glaucoma surgery.

The new designation qualifies Mobius for a research and development tax credit and a waiver of its prescription drug user fee when it seeks an expanded designation, said Ed Timm, president of Mobius.

Ultimately, Mobius would like to pursue an expanded indication for Mitosol that would cover ab interno glaucoma surgery, Timm said. Ab interno glaucoma surgery includes minimally invasive glaucoma surgeries (MIGS). Mitosol is currently indicated as an adjunct to ab externo glaucoma surgery.

“New MIGS procedures, typified by the XEN Gel Stent, have relied upon Mitosol as a companion drug during pivotal clinical trials,” Timm said.

InnFocus, now part of Santen, has also used Mitosol in clinical trials for its MicroShunt MIGS device, Timm said.

St. Louis-based Mobius is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023